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5 (Palma et al., 1998; Garcia-Colunga et al., 2001; Hsiao et al., 2001 ) and other ligand gated ion channels (Huang, 1997) , suggesting that Zn 2+ is a modulator of synaptic activity. Indeed, synaptically released Zn 2+ modulates synaptic activity in the hippocampus (Vogt et al., 2000; Ueno et al., 2002) .
Some neuronal nAChRs, such as α4β2 and α4β4, are potentiated by micromolar Zn 2+ and inhibited by millimolar Zn 2+ (Hsiao et al., 2001) . Others, such as α3β2 (Hsiao et al., 2001 ) and α7 (Palma et al., 1998) , are only inhibited by Zn 2+ . Results with chimeric receptor subunits, and the sensitivity of potentiation to diethylpyrocarbonate and changes in pH, indicate that extracellular histidines participate in forming the potentiating Zn 2+ binding site(s) (Hsiao et al., 2001 ). Here we combine conventional mutagenesis, the substituted cysteine accessibility method (SCAM) and protein modeling to identify residues that are determinants of Zn 2+ potentiation. Our results suggest that neuronal nAChRs bind ACh and Zn 2+ at alternating subunit-subunit interfaces. MOL 15164 7 CaCl 2 , 2.5 KCl, 0.0001 atropine, 10 HEPES, pH7.2). Perfusion was continuous (except during MTSEAbiotin applications) at a rate of ~4 ml/min. ACh alone and in combination with Zn 2+ was applied diluted in perfusion solution. Some experiments were conducted using an OpusXpress 6000A Parallel Oocyte
Voltage Clamp system running OPUSXPRESS 1.1 and CLAMPFIT 9.1 software (Molecular Devices).
In these experiments, all perfusion and application of ACh and Zn 2+ was handled by the OpusXpress system. All Zn 2+ containing solutions were freshly prepared from a 1 M stock of Zn(CH 3 COO) 2 . In previous work, no difference was seen between the effects of Zn(CH 3 COO) 2 and ZnCl 2 containing solutions (Hsiao et al., 2001) . Xenopus oocytes express a Ca ++ -activated Cl -channel that can contribute
to the whole cell current responses when Ca ++ permeable channels, such as neuronal nAChRs, are activated. In previous work (Hsiao et al., 2001) , we found that the extent of zinc potentiation did not vary across a range of holding potentials (-90 mV to -40 mV Wild-type and mutant α4β4 receptors displayed little or no desensitization in response to the low ACh concentrations used here, allowing measurement of Zn 2+ potentiation as follows. Control current in response to ACh was determined from a 1 sec average beginning 29 sec after initiation of agonist application and compared to a 1 sec average of baseline current immediately prior to ACh application.
Current levels during Zn 2+ co-application were determined from a 1 sec average beginning 29 sec after initiation of Zn 2+ application and compared to the control current. Potentiation of wild-type α4β4 and all mutants (with one exception, see below) was determined with 1 µM ACh, which lies between the EC 1 and EC 6 for each receptor. We have previously found that the extent of zinc potentiation of wildThis article has not been copyedited and formatted. The final version may differ from this version. type α4β4 does not vary across this portion of the ACh dose-response curve (Hsiao et al., 2001 ). For one mutant (α4-2E59C β4C75S), 1 µM ACh was the EC 0.2 . For this receptor, we used 5 µM ACh (the EC 2 ) to test potentiation.
Wild-type and mutant α4β2 receptors displayed substantial desensitization upon exposure to ACh, requiring measurement of potentiation or inhibition as previously described (Hsiao et al., 2001 ).
Briefly, the initial 30 sec ACh response in the absence of Zn 2+ was fit to a single exponential decay function. This fit was projected over the next 30 sec during which both ACh and Zn 2+ were co-applied.
The degree of modulation was measured by taking a 1 sec average 29 sec after initiation of Zn 2+ application and comparing it to a 1 sec average of the projected response to ACh alone during the same time period. Thus, both Zn 2+ and control values were taken 59 sec after the initiation of the experiment.
Potentiation of wild-type α4β2 and all mutants was determined with 10 µM ACh, which lies between the EC 14 and EC 24 for each receptor. We have previously found that the extent of zinc potentiation of wild-type α4β2 does not vary across this portion of the ACh dose-response curve (Hsiao et al., 2001) . A similar extent of potentiation was also seen at the lower ACh concentration of 3 µM (the EC 3 ) (Hsiao et al., 2001 ).
In the SCAM experiments in Figure 4A -C, Zn 2+ potentiation was measured before and after a 2-minute incubation with 2mM MTSEA-biotin (Toronto Research Chemicals, Inc., North York, Ontario, Canada). MTSEA-biotin was diluted from a DMSO stock solution into perfusion solution immediately prior to application. The final DMSO concentration of 0.5% had no effect on ACh responses or zinc potentiation (data not shown). Following the incubation, oocytes were rinsed for 5 minutes with perfusion solution prior to measuring Zn 2+ potentiation. The high concentration of MTSEA-biotin and relatively long duration of the incubation were chosen to ensure saturation. Indeed, application of fresh This article has not been copyedited and formatted. The final version may differ from this version. reagent for a further 5 min incubation failed to cause any further loss of potentiation (data not shown).
In some experiments, 1 mM MTSET was used.
In the SCAM reaction rate experiments in Figure 4D , potentiation of the response of α4-2H162C β4C75S to 1 µM ACh by 100 µM Zn 2+ was measured using our standard protocol. 1 µM MTSEAbiotin was then applied for 5 seconds. The oocytes were then rinsed for 5 minutes and potentiation was measured again. This process was repeated and the cumulative exposure times used to determine the reaction rates in the presence and absence of 100 µM Zn 2+ . The concentration of MTSEA-biotin (1 µM) that would yield a measurable reaction rate was determined empirically. Reaction rates were determined by fitting to the single exponential decay equation:
, where Y is the potentiation at time t (in seconds), Y max is the initial potentiation and k is the pseudo-first-order rate constant. The second-order rate constant was obtained by dividing k by the concentration of MTSEA-biotin (Pascual and Karlin, 1998 This article has not been copyedited and formatted. The final version may differ from this version.
Data analysis was performed using PRISM 3 software (GraphPad, San Diego, CA). Statistical significance was assessed using a two-tailed unpaired t-test, or a one-way ANOVA followed by the Dunnett's post-test, as appropriate.
Molecular modeling.
Sequence alignment of the amino-terminal extracellular region of the rat α4 and β4 neuronal nAChR subunits with the AChBP was performed using the ALIGNX module of VECTOR NTI 5 (InforMax, Inc., No. Bethesda, Maryland) . The alignments between the AChBP and α4 and β4
had identity values of 20.4 and 19.4%, respectively. While the sequence identity between the AChBP monomer and amino-terminal extracellular domains of various nAChR subunits is relatively low, the presence of highly conserved ACh binding residues in the AChBP ) and the nicotinic pharmacology of the AChBP suggests that homology modeling of neuronal nAChR extracellular domains using the AChBP structure is appropriate (Le Novere et al., 2002) .
Three-dimensional models were constructed using the program MODELLER 6 (Sali and Blundell, 1993 ) on a Silicon Graphics Indigo2 Extreme workstation. The script "model" was used with neuronal nAChR subunit / AChBP alignments. Disulfide bonds in the AChBP template structure were explicitly included during homology model refinement. The amino-terminal extracellular domain sequences of the α4 and β4 subunits were modeled using the AChBP pentamer structure ) (PDB ID: 1I9B) to get initial coordinates for an α4β4 pentamer (subunit ordering of αβαββ).
Ten models were produced with energy refinement handled within the program. Conditions were optimized such that resulting structures exhibited energies in line with current published nicotinic receptor homology models (Le Novere et al., 2002; Everhart et al., 2003) . The lowest energy structure was then inspected visually and with PROCHECK (Laskowski et al., 1993) for inappropriate stereochemistry (clashing side chains, disallowed torsion angles, etc.). In only one case, did a residue This article has not been copyedited and formatted. The final version may differ from this version.
require manual adjustment using the O software package (Jones et al., 1991) . Further minimization was then carried out using the CNS software package (Brünger, 1998) , with twenty cycles of conjugate gradient. The CNS minimized structure was then reanalyzed with PROCHECK to ensure stereochemical soundness. The images in Figures 1B and 6 were produced using RIBBONS (Carson, 1997 
Results
The effect of 100 µM Zn 2+ on current responses induced by low concentrations of ACh varies from inhibition of α3β2 receptors to greater than 5-fold potentiation of α4β4 receptors, with the α3β4 and α4β2 receptors displaying intermediate levels of potentiation ( Figure 1A ). The large difference in the effect of Zn 2+ on α4β4 and α3β2 receptors suggested a strategy for identifying the site at which Zn 2+ binds and potentiates neuronal nAChRs; mutagenesis of residues present in α4 and β4, but not in α3 and β2.
Amino acid residues that most commonly form Zn 2+ -binding sites include histidines, free cysteines, aspartates and glutamates (Glusker, 1991) . Our previous work indicated the involvement of extracellular histidine residues (Hsiao et al., 2001 ) and so we used site-directed mutagenesis to test the role of the seven histidine residues unique to the extracellular portions of α4 and β4. We also examined the two unique extracellular free cysteine residues. Our screen included five residues within the aminoterminal extracellular domain of α4 (H2, H61, H104, H109, H162), two residues within this region of β4 (C75, H157), one residue within the carboxy-terminal extracellular portion of α4 (C594) and one residue within the carboxy-terminal extracellular portion of β4 (H469). At some positions, the residue was changed to the residue present at that position in α3 or β2, as appropriate. For α4H2, α4H104 and β4C75 the residues present in α3 and β2 might also be Zn 2+ -coordinating (glutamate, aspartate and aspartate, respectively). Thus, in addition to testing α4H2E and α4H104D mutants, we also tested the alanine mutants, α4H2A and α4H104A. For β4C75, we tested a serine mutant. To test the role of α4C594, we used a naturally occurring splice variant (α4-2), which lacks this C-terminal cysteine (Goldman et al., 1987) . The positions of these residues within an alignment of α3, α4, β2 and β4 are shown in Figure 1C . To visualize the positions of these residues within the receptor structure we This article has not been copyedited and formatted. The final version may differ from this version. generated a homology model of the extracellular domain of the (α4) 2 (β4) 3 pentamer, using the AChBP ) as a template structure (see Materials and Methods). Many of these residues are located at the non-ACh-binding subunit-subunit interfaces within the pentamer ( Figure 1B ).
We used the α4β4 receptor as our primary target to allow analysis of α4 and β4 residues in the same receptor. The α4β4 receptor is also convenient because it displays the greatest degree of zinc potentiation, expresses well in oocytes and shows little or no desensitization in response to low ACh concentrations. The role of critical residues in α4 was also confirmed with α4β2 (see below), a major nAChR subtype in the mammalian CNS (Corringer et al., 2000) . Mutant α4 and β4 subunits were coexpressed in Xenopus oocytes with wild-type β4 or α4 subunits, respectively. ACh dose-response curves, constructed for each mutant receptor, showed that the mutations had little or no effect on ACh sensitivity (Table 1) . We used 100 µM Zn 2+ to test the effect of each mutation because 100 µM Zn 2+ lies at the peak of the biphasic potentiation-inhibition curve for α4β4 (Hsiao et al., 2001 ). Thus, reductions in maximal potentiation, or shifts in the curve would be detected. When compared to wildtype α4β4 receptors, some mutant receptors (such as α4H162Gβ4) displayed reduced potentiation by 100 µM Zn 2+ (45±4% of wild-type), while others (such as α4β4C75S) displayed potentiation similar to that of wild-type α4β4 ( Figure 2A ). In addition to α4H162G, the α4H61N and β4H469Y mutations also caused significant decreases in potentiation by 100 µM Zn 2+ ( Figure 2B , Table 2 ). The α4-2β4
receptor (which lacks the C-terminal cysteine) displayed an increase in potentiation, suggesting potential involvement in the allosteric pathway. However, because we are focused on identifying the zinc potentiation site, we chose not to pursue this possibility. In our model of the α4β4 extracellular domain, the side chains of β4D195 and α4E59 are near the side chain of α4H162 ( Figure 1B ). Because D195 is conserved in both the β2 and β4 subunits, we substituted an alanine at this position. We also prepared a α4E59A mutant. The α4E59Aβ4 receptor displayed significantly reduced potentiation by 100 µM Zn 2+ , while the α4β4D195A receptor did not differ from wild type α4β4 ( Figure 2B ). The results of this mutagenesis screen identifies α4E59, α4H61, α4H162 and β4H469 as candidates for involvement in forming the zinc potentiation site.
In Figure 3A , we examined the effects of a range of zinc concentrations on wild type and mutant α4β4 receptors. The α4E59A, α4H61N, α4H162G and β4H469Y mutations each reduced maximal potentiation by Zn 2+ , but none of the mutations increased the EC 50 for zinc potentiation, as might be expected if the mutations were damaging a zinc-binding site (Table 2 ). However, a simple rightward shift in the zinc dose-response curve could be expected only if zinc potentiation were occurring in isolation. We have previously shown that zinc both potentiates and inhibits these receptors at separate sites. At and above 300 µM Zn 2+ , receptor inhibition of the α4β4 receptor becomes apparent, leading to a distinctly biphasic Zn 2+ dose-response curve (Hsiao et al., 2001) . If the mutations were causing damage to the potentiation site, while leaving the inhibition site intact, a rightward shift in the potentiation curve could be obscured.
To investigate this issue in more detail, we examined the effects of a wider range of Zn 2+ concentrations on the α4H162Gβ4 mutant ( Figure 3B ). Obtaining accurate values from fitting biphasic zinc dose-response data to a two-site equation is difficult due to the close proximity of potentiating and inhibiting phases (Hsiao et al., 2001) . However, in this earlier study we found that diethylpyrocarbonate (DEPC) treatment eliminates potentiation, without affecting inhibition, of the α4β4 receptor. We fit this data to a single site inhibition equation to obtain an IC 50 for Zn 2+ inhibition of 362 ± 70 µM (see Materials and Methods). We then fit the biphasic zinc dose-response data for wild-type α4β4 in our earlier study to a two-site equation (see Materials and Methods) using this IC 50 value as a constant. This allowed us to estimate parameters for zinc potentiation of the wild type α4β4 receptor (EC 50 = 110 ± 33 µM, n H = 0.96 ± 0.04, Maximal Potentiation = 1400 ± 250%). The EC 50 value is 4-fold greater and the This article has not been copyedited and formatted. The final version may differ from this version. (Hsiao et al., 2001) , it is unlikely to be affected by mutations at the zinc potentiation site. This allows us to use the inhibition parameters obtained from fitting the post-DEPC treatment wild-type α4β4 receptor when fitting the data obtained for the α4H162Gβ4 mutant. If we also assume that maximal potentiation is not changing, we find that upon fitting to a two site equation, the EC 50 for zinc potentiation of the α4H162Gβ4 mutant is greater (267 ± 7 µM) than the value for wild type α4β4. This analysis suggests, but does not prove, that the α4H162Gβ4 receptor is indeed less sensitive to zinc potentiation than wild type α4β4. In order to prove this conclusively using dose-response analysis, we would need to be able to examine potentiation in the absence of inhibition. However, we have been unable to eliminate, or even damage, the inhibition of nAChRs by zinc (Hsiao et al., 2001) . None of the mutations we have examined reduce inhibition by high concentrations of zinc (data not shown). Thus, we turned to other approaches to provide additional information about the role of candidate residues in forming the zinc potentiation site.
First, we examined the effect of double mutant combinations, reasoning that simultaneous mutation of two residues involved in mediating zinc potentiation should yield an effect greater than with either single mutation. Because the α4H162G mutant displayed the greatest loss of Zn 2+ potentiation, we used this receptor as a point of reference. Each of the other 3 mutations was examined as a double mutant with α4H162G. The α4H61N and β4H469Y mutations failed to alter potentiation of the α4H162G β4 receptor. Potentiation of these double mutants by 100µM Zn 2+ was 107±7% and 99±7%
of the potentiation of the α4H162G single mutant, respectively. This result suggests that these residues might not play important roles in mediating Zn 2+ potentiation. In contrast, receptors formed by the double mutant α4E59A, H162G displayed significantly decreased potentiation when compared to the This article has not been copyedited and formatted. The final version may differ from this version. As an alternative approach to testing the role of candidate residues in forming a zinc potentiation site, we turned to the substituted cysteine accessibility method (SCAM) (Karlin and Akabas, 1998) . In SCAM analysis, a cysteine is placed at the position of interest and function is then measured before and after reaction with a methanethiosulfonate (MTS) reagent. While free cysteines can participate in coordination of Zn 2+ , they often do not substitute effectively for other coordinating residues (Paoletti et al., 2000) . This is most likely due to stringent spatial requirements for the relevant atoms (S, N and O)
to be able to coordinate the zinc ion. The result of our double mutant experiments (see above) suggest that even if a substituted cysteine failed to directly participate in Zn 2+ coordination (thus constituting a single mutant), the functional damage to the site would be partial. A further reduction of Zn 2+ potentiation after reaction with an MTS reagent would then suggest a physical proximity to the zinc ion and would strengthen the case for direct coordination. As the MTS reagent for most of our experiments, we used MTSEA-biotin, a large, relatively membrane impermeant MTS reagent that has been used to characterize various sites on GABA A receptors (Teissere and Czajkowski, 2001; Wagner and Czajkowski, 2001 ). To avoid the potential for confounding effects of the MTS reagent acting at other free cysteines, the α4-2 β4C75S mutant receptor, which lacks extracellular free cysteine residues, was used as a "pseudo-wild-type" background (Karlin and Akabas, 1998) in which to test each cysteine mutant. This pseudo-wild-type receptor displayed ACh sensitivity and Zn 2+ potentiation similar to that of true wild-type α4β4 and was unaffected by MTSEA-biotin treatment (Tables 1 and 2 , Figure 4A and
This article has not been copyedited and formatted. The final version may differ from this version. potentiation of the α4H61C receptor ( Figure 4C ), again suggesting that α4H61 may not play an important role in mediating Zn 2+ potentiation. In contrast, MTSEA-biotin treatment significantly reduced potentiation of the α4E59C and α4H162C receptors, suggesting that α4E59 and α4H162 are located at or near the Zn 2+ -binding site ( Figure 4B and C). However, as was the case for the double mutant, these MTSEA-biotin treated mutant receptors retained some ability to be potentiated by Zn 2+ .
In Figure 4 , we used 1 µM ACh to test potentiation of the pseudo-wild-type receptor, as well as the α4H61C and α4H162C receptors. However, we used the equipotent concentration of 5 µM ACh to test potentiation of the α4E59C (see Materials and Methods). We also tested the ability of MTSEA-biotin to reduce zinc potentiation of the α4E59C using 1µM ACh, finding post-treatment potentiation to be 76 ± 4% of pre-treatment potentiation (p<0.05, n=6). Zinc potentiation could also be reduced by MTSET application (1 mM, 2 min). While the trimethylammonium ethyl group deposited by MTSET is substantially smaller than the biotinylaminoethyl group deposited by MTSEA-biotin, it does have a positive charge that would be likely to interfere with Zn 2+ binding. Post-treatment potentiation of α4-2H162C β4C75S by 100 µM Zn 2+ was 71 ± 3% of pretreatment potentiation (n = 6, p < 0.001) and for α4-2E59C β4C75S the value was 83 ± 3% of pretreatment potentiation (n = 3, p < 0.05). The effects of MTSEA-biotin and MTSET on zinc potentiation of the α4E59C mutant were substantially less than the effects on the α4H162C mutant. This may be due, in part, to fact that substituting a cysteine for α4E59 had a greater effect on zinc potentiation than did substitution of α4H162 (61±5% and 77±2% remaining This article has not been copyedited and formatted. The final version may differ from this version. potentiation, respectively). Thus, there is less remaining potentiation to be affected by the MTS reagent. However, it is also possible that while α4E59 may be near the site of zinc binding, it might not be directly participating in coordination of the zinc ion.
SCAM can also be used to obtain information about the relative accessibility of a site under different conditions (Karlin and Akabas, 1998) . By alternating short exposures to low concentrations of MTS reagent with functional measurements, a reaction rate (and thus a relative measure of accessibility)
can be determined (Pascual and Karlin, 1998) . In Figure 4D , we use this methodology to examine the relative accessibility for MTSEA-biotin at position 162 of α4 in the presence and absence of Zn 2+ .
Oocytes expressing α4-2H162C β4C75S were exposed to 1 µM MTSEA-biotin in 5 sec increments.
After each application, the oocytes were rinsed and the extent of potentiation by 100 µM Zn 2+ was determined. The decline in Zn 2+ potentiation upon repeated exposure to MTSEA-biotin was then fit to an exponential decay function. In the absence of Zn 2+ , the halftime of the reaction was 8.7 sec, yielding a rate of 79,000 ± 14,000 M -1 s -1 . In the presence of 100 µM Zn 2+ , the halftime of the reaction was 21.3 sec, yielding a rate of 32,000 ± 10,000 M -1 s -1 . Despite the change in reaction rate, the extent of the effect was the same in the presence and absence of Zn 2+ (the fit plateau was 0.69±0.05 and 0.65±0.02, respectively). The significant decrease in reaction rate (p<0.01) indicates that the site is less accessible to MTSEA-biotin when Zn 2+ is present and suggests that Zn 2+ is competing with MTSEA-biotin for occupation of the site.
In addition to potentiation of the ACh response, zinc potentiates the response of neuronal nAChRs to nicotine. Potentiation of α4β4 by coapplication of 100 µM Zn 2+ with 1µM nicotine was 444 ± 43% of the response to nicotine alone. The α4H162G and α4E59A mutant receptors each displayed significantly reduced potentiation by 100 µM Zn 2+ (50±5% of wild-type α4β4, p<0.05 and 88±4% of wild-type α4β4, p<0.01, respectively).
This article has not been copyedited and formatted. The final version may differ from this version. context: α4β2 ( Figure 5 ). The α4β2 is a major nAChR subtype in the CNS (Corringer et al., 2000) .
The effect of zinc on α4β2 receptors was substantial, with a maximum potentiation of approximately 2.5-fold achieved at 50 µM Zn 2+ ( Figures 1A and 5A , and see Hsiao et al., 2001) . The α4E59A and α4H162G mutations were each able to significantly reduce the extent of potentiation by 50 µM Zn 2+ ( Figure 5B ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
We have identified α4E59 and α4H162 as determinants of Zn 2+ potentiation on rat neuronal nAChRs. The positions of these residues within our receptor model are shown in Figure 6 . A strong case can be made for direct coordination of the zinc ion by α4H162. Mutation of this residue results in a large loss of zinc potentiation, MTSEA-biotin has a substantial effect when a cysteine is at this position and zinc can slow the reaction of MTSEA-biotin with a cysteine at this position. While the side chain on α4E59 is close enough to the side chain of α4H162 (in Figure 1B , the εN of H162 is 5.6 Å from the nearest carboxyl oxygen in E59) for a role in coordination to be plausible (Harding, 2001) , the effects of mutation and MTSEA-biotin treatment are substantially less than what is seen at position 162. Thus, while α4H162 is likely to be participating in direct coordination of the zinc ion, α4E59 may only be near the zinc potentiation site without actually participating in zinc coordination.
The location of zinc potentiation sites on neuronal nAChRs
The positions of α4H162 and α4E59 within the receptor and the involvement of both α and β subunits in mediating Zn 2+ potentiation (Hsiao et al., 2001) suggest that neuronal nAChRs bind Zn 2+ at subunit-subunit interfaces that alternate with ACh binding interfaces. This depends on our decision to model the receptor with a subunit arrangement of αβαββ. Whether the fifth subunit is β or α is irrelevant. In either case the receptor would have 2 ACh-binding and 2 zinc-binding interfaces. More important is the arrangement of the first 4 subunits in an alternating αβαβ pattern. This arrangement appears to be required. The subunits of the AChBP are arranged in a rotationally symmetric manner, with each subunit supplying a "principal" face to one ACh binding site and a "complementary" face to
another ACh binding site Celie et al., 2004) . In heteromeric neuronal nAChRs, the "principal" residues are only present on the α subunit, while the "complementary" residues are only This article has not been copyedited and formatted. The final version may differ from this version. present on the β subunit (Corringer et al., 2000) . Thus, both α and β subunits are required to form an ACh binding site. Regardless of whether the α:β stoichiometry is 2:3 or 3:2, only two non-adjacent interfaces will form ACh binding sites. An additional two non-adjacent interfaces would form Zn 2+ -binding sites.
Neuronal nAChRs also form as homopentamers of the α7 subunit (Corringer et al., 2000) . The α7 subunit lacks both H162 and E59 (Le Novere and Changeux, 2001) , and α7 homopentamers are thought to bind ACh at all five interfaces (Corringer et al., 2000) . As would be expected, α7 homomers are not potentiated by Zn 2+ (Palma et al., 1998) . A novel Zn 2+ -activated channel (ZAC) has been reported (Davies et al., 2003) . This homomeric receptor is structurally homologous to nAChRs. While ZAC subunits have a histidine in a similar position as α4H162, no aspartates or glutamates are located near the position analogous to α4E59. It is unclear if the ZAC binds Zn 2+ at a site similar to the potentiation site we have identified on neuronal nAChRs.
We have identified at least one residue (α4H162) as part of a pair of identical Zn 2+ potentiation sites on neuronal nAChRs. Because Zn 2+ -binding sites can have 4, 5 or 6 coordination points (Glusker, 1991) , additional residues remain to be identified. These receptors may also possess a second class of Zn 2+ potentiation site. In our single mutation experiments, only partial losses of potentiation were observed. This was not unexpected. However, even the double mutant α4E59A, H162G retained a modest ability to be potentiated by Zn 2+ application (approximately one-third of wild-type potentiation).
In our SCAM experiments, we also did not completely eliminate potentiation. This contrasts with the complete elimination of potentiation upon diethypyrocarbonate treatment (Hsiao et al., 2001 ). Thus, neuronal nAChRs might possess at least three distinct classes of Zn 2+ binding site, a major potentiation site accounting for roughly 2/3 of the potentiation (identified here), a minor potentiation site accounting for roughly 1/3 of the potentiation and an inhibitory site. Glutamate, GABA and glycine receptors also This article has not been copyedited and formatted. The final version may differ from this version. (Paoletti et al., 2000; Laube et al., 2002; Hosie et al., 2003) .
Zinc potentiation sites have structural similarities to ACh binding sites
We compared the zinc potentiation site with other binding sites on cys-loop receptors. The ACh binding site on nAChRs has been extensively characterized (Corringer et al., 2000) . E59 is located within the "D-loop" region of α4. In an ACh-binding interface, the D-loop is supplied by the γ, δ or ε subunits of muscle nAChRs or the β subunits of neuronal nAChRs and contributes a critical tryptophan residue to the binding site, as well as several determinants of pharmacological diversity (Corringer et al., 2000; Celie et al., 2004) . H162 is located within the "F loop" region of α4. At ACh binding interfaces, this region is also supplied by the "non-α" subunits of muscle and neuronal nAChRs and contains determinants of pharmacological diversity (Corringer et al., 2000) . Thus, the Zn 2+ -binding site that we have identified has structural similarity to the ACh binding site.
Zinc potentiation sites are not related to calcium potentiation sites on neuronal nAChRs
Neuronal nAChRs are also potentiated by extracellular Ca 2+ (Mulle et al., 1992; Vernino et al., 1992) . Critical glutamate residues mediating Ca 2+ potentiation have been identified on α7 (Galzi et al., 1996) . These residues are highly conserved among neuronal nAChRs and correspond to α4E45/β4E49
(located between β strands 1 and 2) and α4E175/β4E179 (located just before β strand 9). Both putative Ca 2+ binding sites are located at the bottom (proximal to the membrane) of the receptor structure shown in Figure 1B , away from the Zn 2+ potentiation site we have identified. Also, Ca 2+ potentiation of α4β4
is unaffected by the α4H162G and α4E59A mutations (data not shown (Laube et al., 2002) . The Zn 2+ site that we have identified on neuronal nAChRs is not structurally comparable to either of these sites. GABA A receptors also possess multiple Zn 2+ -binding sites. For clarity, it is important to remember that GABA A receptor β subunits are equivalent to neuronal nAChR α subunits, while GABA A receptor α subunits are equivalent to neuronal nAChR β subunits. Thus, while neuronal nAChRs bind ACh at α-β interfaces, GABA receptors bind GABA at β-α interfaces (Smith and Olsen, 1995) . In the α1β3 GABA A receptor, α1E137, α1H141 and β3E182 participate in a Zn 2+ -binding inhibitory site located at α-β interfaces (non-GABA binding interfaces) near the bottom (proximal to the cell surface) of the receptor extracellular domain (Hosie et al., 2003) . A separate class of Zn 2+ -binding inhibitory site is located within the ion channel. The Zn 2+ -potentiation site we have identified on neuronal nAChRs is not structurally comparable to either of these Zn 2+ -binding sites on GABA A receptors. Glutamate gated ion channels also possess zinc-binding sites, which have been characterized in detail (Paoletti et al., 2000) . However, these receptors are structurally unrelated to nAChRs, precluding a comparison with the Zn 2+ -potentiation site on neuronal nAChRs.
Zinc potentiation sites are analogous to the benzodiazepine-binding site on GABA A receptors
The most interesting comparison is with the binding site for benzodiazepines on GABA A receptors. While GABA binds at β-α interfaces, incorporation of a γ subunit allows benzodiazepines to This article has not been copyedited and formatted. The final version may differ from this version. bind at the α-γ interface (Smith and Olsen, 1995) . A series of residues on the γ2 subunit (Y58, F77, A79, T81) have been identified as components of the benzodiazepine-binding site (Kucken et al., 2000; Teissere and Czajkowski, 2001; Kucken et al., 2003) . Examination of aligned amino acid sequences (Le Novere and Changeux, 2001 ) and a model of the α1β2γ2 GABA A receptor extracellular domain (Kucken et al., 2003) reveals that the benzodiazepine-binding site residue γ2T81 (Teissere and Czajkowski, 2001 ) is in a location identical to that of α4E59. While α4E59 may not directly coordinate This article has not been copyedited and formatted. The final version may differ from this version. Results are presented as the ratio of mutant receptor potentiation to the potentiation of wild type receptor in the same batch of oocytes (mean ± SEM, n = 3-14). The ACh concentration for all receptors is 1 µM.
Significant differences in Zn 2+ potentiation as compared to wild-type α4β4 are indicated (***p<0.001, **p<0.01, *p<0.05). 
